Stage-dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure

Miki Nonaka, Sachio Morimoto, Takashi Murayama, Nagomi Kurebayashi, Lei Li, Yuan Yuan Wang, Masaki Arioka, Tatsuya Yoshihara, Fumi Takahashi-Yanaga, Toshiyuki Sasaguri

研究成果: ジャーナルへの寄稿記事

8 引用 (Scopus)

抄録

Background and Purpose The Ca2+ sensitizer pimobendan is a unique inotropic agent that improves cardiac contractility with less of an increase in oxygen consumption and potentially fewer adverse effects on myocardial remodelling and arrhythmia, compared with traditional inotropes. However, clinical trials report contradictory effects of pimobendan in patients with heart failure (HF). We provide mechanistic experimental evidence of the efficacy of pimobendan using a novel mouse model of progressive HF. Experimental Approach A knock-in mouse model of human genetic dilated cardiomyopathy, which shows a clear transition from compensatory to end-stage HF at a fixed time during growth, was used to evaluate the efficacy of pimobendan and explore the underlying molecular and cellular mechanisms. Key Results Pimobendan prevented myocardial remodelling in compensated HF and significantly extended life span in both compensated and end-stage HF, but dose-dependently increased sudden death in end-stage HF. In cardiomyocytes isolated from end-stage HF mice, pimobendan induced triggered activity probably because of early or delayed afterdepolarizations. The L-type Ca2+ channel blocker verapamil decreased the incidence of triggered activity, suggesting that this was from over-elevated cytoplasmic Ca2+ through increased Ca2+ entry by PDE3 inhibition under diminished sarcoplasmic reticulum Ca2+ reuptake and increased Ca2+ leakage from sarcoplasmic reticulum in end-stage HF. Conclusions and Implications Pimobendan was beneficial regardless of HF stage, but increased sudden cardiac death in end-stage HF with extensive remodelling of Ca2+ handling. Reduction of cytoplasmic Ca2+ elevated by PDE3 inhibition might decrease this risk of sudden cardiac death.

元の言語英語
ページ(範囲)2369-2382
ページ数14
ジャーナルBritish Journal of Pharmacology
172
発行部数9
DOI
出版物ステータス出版済み - 1 5 2015

Fingerprint

Dilated Cardiomyopathy
Heart Failure
Sudden Cardiac Death
Sarcoplasmic Reticulum
pimobendan
Medical Genetics
Verapamil
Sudden Death
Cardiac Myocytes
Oxygen Consumption
Cardiac Arrhythmias
Clinical Trials
Incidence

All Science Journal Classification (ASJC) codes

  • Pharmacology

これを引用

Stage-dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure. / Nonaka, Miki; Morimoto, Sachio; Murayama, Takashi; Kurebayashi, Nagomi; Li, Lei; Wang, Yuan Yuan; Arioka, Masaki; Yoshihara, Tatsuya; Takahashi-Yanaga, Fumi; Sasaguri, Toshiyuki.

:: British Journal of Pharmacology, 巻 172, 番号 9, 05.01.2015, p. 2369-2382.

研究成果: ジャーナルへの寄稿記事

Nonaka, M, Morimoto, S, Murayama, T, Kurebayashi, N, Li, L, Wang, YY, Arioka, M, Yoshihara, T, Takahashi-Yanaga, F & Sasaguri, T 2015, 'Stage-dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure', British Journal of Pharmacology, 巻. 172, 番号 9, pp. 2369-2382. https://doi.org/10.1111/bph.13062
Nonaka, Miki ; Morimoto, Sachio ; Murayama, Takashi ; Kurebayashi, Nagomi ; Li, Lei ; Wang, Yuan Yuan ; Arioka, Masaki ; Yoshihara, Tatsuya ; Takahashi-Yanaga, Fumi ; Sasaguri, Toshiyuki. / Stage-dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure. :: British Journal of Pharmacology. 2015 ; 巻 172, 番号 9. pp. 2369-2382.
@article{b2ed3b5a68164b88b6428c50481f2110,
title = "Stage-dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure",
abstract = "Background and Purpose The Ca2+ sensitizer pimobendan is a unique inotropic agent that improves cardiac contractility with less of an increase in oxygen consumption and potentially fewer adverse effects on myocardial remodelling and arrhythmia, compared with traditional inotropes. However, clinical trials report contradictory effects of pimobendan in patients with heart failure (HF). We provide mechanistic experimental evidence of the efficacy of pimobendan using a novel mouse model of progressive HF. Experimental Approach A knock-in mouse model of human genetic dilated cardiomyopathy, which shows a clear transition from compensatory to end-stage HF at a fixed time during growth, was used to evaluate the efficacy of pimobendan and explore the underlying molecular and cellular mechanisms. Key Results Pimobendan prevented myocardial remodelling in compensated HF and significantly extended life span in both compensated and end-stage HF, but dose-dependently increased sudden death in end-stage HF. In cardiomyocytes isolated from end-stage HF mice, pimobendan induced triggered activity probably because of early or delayed afterdepolarizations. The L-type Ca2+ channel blocker verapamil decreased the incidence of triggered activity, suggesting that this was from over-elevated cytoplasmic Ca2+ through increased Ca2+ entry by PDE3 inhibition under diminished sarcoplasmic reticulum Ca2+ reuptake and increased Ca2+ leakage from sarcoplasmic reticulum in end-stage HF. Conclusions and Implications Pimobendan was beneficial regardless of HF stage, but increased sudden cardiac death in end-stage HF with extensive remodelling of Ca2+ handling. Reduction of cytoplasmic Ca2+ elevated by PDE3 inhibition might decrease this risk of sudden cardiac death.",
author = "Miki Nonaka and Sachio Morimoto and Takashi Murayama and Nagomi Kurebayashi and Lei Li and Wang, {Yuan Yuan} and Masaki Arioka and Tatsuya Yoshihara and Fumi Takahashi-Yanaga and Toshiyuki Sasaguri",
year = "2015",
month = "1",
day = "5",
doi = "10.1111/bph.13062",
language = "English",
volume = "172",
pages = "2369--2382",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Stage-dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure

AU - Nonaka, Miki

AU - Morimoto, Sachio

AU - Murayama, Takashi

AU - Kurebayashi, Nagomi

AU - Li, Lei

AU - Wang, Yuan Yuan

AU - Arioka, Masaki

AU - Yoshihara, Tatsuya

AU - Takahashi-Yanaga, Fumi

AU - Sasaguri, Toshiyuki

PY - 2015/1/5

Y1 - 2015/1/5

N2 - Background and Purpose The Ca2+ sensitizer pimobendan is a unique inotropic agent that improves cardiac contractility with less of an increase in oxygen consumption and potentially fewer adverse effects on myocardial remodelling and arrhythmia, compared with traditional inotropes. However, clinical trials report contradictory effects of pimobendan in patients with heart failure (HF). We provide mechanistic experimental evidence of the efficacy of pimobendan using a novel mouse model of progressive HF. Experimental Approach A knock-in mouse model of human genetic dilated cardiomyopathy, which shows a clear transition from compensatory to end-stage HF at a fixed time during growth, was used to evaluate the efficacy of pimobendan and explore the underlying molecular and cellular mechanisms. Key Results Pimobendan prevented myocardial remodelling in compensated HF and significantly extended life span in both compensated and end-stage HF, but dose-dependently increased sudden death in end-stage HF. In cardiomyocytes isolated from end-stage HF mice, pimobendan induced triggered activity probably because of early or delayed afterdepolarizations. The L-type Ca2+ channel blocker verapamil decreased the incidence of triggered activity, suggesting that this was from over-elevated cytoplasmic Ca2+ through increased Ca2+ entry by PDE3 inhibition under diminished sarcoplasmic reticulum Ca2+ reuptake and increased Ca2+ leakage from sarcoplasmic reticulum in end-stage HF. Conclusions and Implications Pimobendan was beneficial regardless of HF stage, but increased sudden cardiac death in end-stage HF with extensive remodelling of Ca2+ handling. Reduction of cytoplasmic Ca2+ elevated by PDE3 inhibition might decrease this risk of sudden cardiac death.

AB - Background and Purpose The Ca2+ sensitizer pimobendan is a unique inotropic agent that improves cardiac contractility with less of an increase in oxygen consumption and potentially fewer adverse effects on myocardial remodelling and arrhythmia, compared with traditional inotropes. However, clinical trials report contradictory effects of pimobendan in patients with heart failure (HF). We provide mechanistic experimental evidence of the efficacy of pimobendan using a novel mouse model of progressive HF. Experimental Approach A knock-in mouse model of human genetic dilated cardiomyopathy, which shows a clear transition from compensatory to end-stage HF at a fixed time during growth, was used to evaluate the efficacy of pimobendan and explore the underlying molecular and cellular mechanisms. Key Results Pimobendan prevented myocardial remodelling in compensated HF and significantly extended life span in both compensated and end-stage HF, but dose-dependently increased sudden death in end-stage HF. In cardiomyocytes isolated from end-stage HF mice, pimobendan induced triggered activity probably because of early or delayed afterdepolarizations. The L-type Ca2+ channel blocker verapamil decreased the incidence of triggered activity, suggesting that this was from over-elevated cytoplasmic Ca2+ through increased Ca2+ entry by PDE3 inhibition under diminished sarcoplasmic reticulum Ca2+ reuptake and increased Ca2+ leakage from sarcoplasmic reticulum in end-stage HF. Conclusions and Implications Pimobendan was beneficial regardless of HF stage, but increased sudden cardiac death in end-stage HF with extensive remodelling of Ca2+ handling. Reduction of cytoplasmic Ca2+ elevated by PDE3 inhibition might decrease this risk of sudden cardiac death.

UR - http://www.scopus.com/inward/record.url?scp=84926676659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926676659&partnerID=8YFLogxK

U2 - 10.1111/bph.13062

DO - 10.1111/bph.13062

M3 - Article

C2 - 25560565

AN - SCOPUS:84926676659

VL - 172

SP - 2369

EP - 2382

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 9

ER -